Myeloma

Bispecific antibodies
#Bispecific Antibodies #European Commission #Johnson & Johnson #Myeloma #Oncology

EC okays immunotherapy double regimen for multiple myeloma

The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care.  The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have… Read More

#News #Regulatory

Cytokine release syndrome
#Clinical trial #Cytokine Release Syndrome (CRS) #Immunotherapy #Myeloma #Oncology

New drug could improve access to immunotherapies

A UK-led clinical trial has opened at The Christie NHS Foundation Trust in Manchester to test a new drug that could make immunotherapy safer and more accessible for patients with multiple myeloma.  The trial, called TOPICAL, is led by The Christie NHS Foundation Trust and will take… Read More

#Cancer Research #News

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 30 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More

#Podcasts

#AI #ASCO #Cancer research #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

DDW Highlights: 23 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More

#Podcasts

#AI #ASCO #Cancer Research UK #Clinical trial #Combination therapy #Data science #GLP-1 #Incyte #MHRA #Myeloma #Obesity #Oncology #UK #Ulcerative colitis (UC) #Weight loss

This week in Drug Discovery (15 June – 19 June) 

News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW.  This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research.  The top stories:     … Read More

#News

Myeloma
#Clinical trial #Combination therapy #Myeloma

Therapy enables 89% survival rate in myeloma patients 

A combination treatment has demonstrated strong survival rates in patients with earlier-line relapsed or refractory multiple myeloma.  Talvey (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide showed a progression-free survival rate of up to 81.3% versus standard of care (51.2%) and an overall survival… Read More

#Cancer Research #News

Multiple myeloma
#Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends quadruplet regimen for multiple myeloma 

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) as a combination therapy for untreated multiple myeloma.  NICE recommended the therapy, developed by Johnson & Johnson, with bortezomib, lenalidomide and dexamethasone (D-VRd) for untreated multiple myeloma in adults when an autologous stem cell transplant (ASCT)… Read More

#News #Regulatory

Myeloma
#HaemaLogiX #Myeloma #Phase I trial

HaemaLogiX launches Phase I multiple myeloma trial 

Biotechnology company HaemaLogiX has begun patient enrolment for a Phase I study evaluating a therapy for multiple myeloma.  The KOALA study is a Phase I dose‑escalation trial assessing the safety and preliminary efficacy of KMCAR T‑cell, a novel autologous CAR‑T therapy targeting the Kappa Myeloma Antigen (KMA), a tumour‑specific receptor… Read More

#News

#Cancer research #Drug discovery #Enzymes #Myeloma #Parkinson's #University of Edinburgh

DDW Highlights: 26 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer enzyme discovery provided clues for potential new treatments. Elsewhere, how can… Read More

#Podcasts

#Bacteria #Blood cancer #Cancer Research UK #HaemaLogiX #Haematology #Institute of Cancer Research #Myeloma #Neuroscience #NHS #Oncology #Orphan drugs #Parkinson's #Rare diseases #University of Edinburgh

This week in Drug Discovery (16 – 20 March) 

News round-up for 16 – 20 March February by Bruno Quinney, Content Team at DDW.  This week, a pioneering method is being used to make drugs for Parkinson’s disease. Elsewhere, advances have been made in both research and trials for common cancers.  The top stories:    Edinburgh team… Read More

#News

CAR-T in multiple myeloma
#Australia #CAR-T #Myeloma

TGA approves trial for first-in-human multiple myeloma therapy

Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma.  The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum Cancer Centre (Peter Mac), is a KMA.CAR T-cell immunotherapy. The novel autologous CAR-T cell therapy targets Kappa Myeloma Antigen (KMA), a receptor… Read More

#News #Regulatory

Multiple myeloma
#Cancer drug targets #HaemaLogiX #Haematology #Myeloma #Oncology

Research identifies new targets for multiple myeloma treatment

New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.  These antigens are present on malignant plasma cells but… Read More

#Cancer Research #News

Blood cancer
#Myeloma #Oncology #Phase II trial #Starton Therapeutics

STAR-LLD seeks to replace standard care for blood cancers

Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM).  STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More

#Cancer Research #News